Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction

L Ungar, A Altmann, MD Greicius - Brain imaging and behavior, 2014 - Springer
Alzheimer’s disease (AD) is an increasingly prevalent, fatal neurodegenerative disease that
has proven resistant, thus far, to all attempts to prevent it, forestall it, or slow its progression. …

Reflection and reasoning in moral judgment

JM Paxton, L Ungar, JD Greene - Cognitive science, 2012 - Wiley Online Library
While there is much evidence for the influence of automatic emotional responses on moral
judgment, the roles of reflection and reasoning remain uncertain. In Experiment 1, we induced …

[HTML][HTML] Patient-reported satisfaction and study drug discontinuation: post-hoc analysis of findings from ROCKET AF

L Ungar, F Rodriguez, AS Hellkamp, RC Becker… - Cardiology and …, 2019 - Springer
Introduction Patient-reported outcomes (PROs) and satisfaction endpoints are increasingly
important in clinical trials and may be associated with treatment adherence. In this post hoc …

Racial differences in quality of care and outcomes after acute coronary syndrome

CM Yong, L Ungar, F Abnousi, SM Asch… - The American journal of …, 2018 - Elsevier
Guideline adherence and variation in acute coronary syndrome (ACS) outcomes by race in
the modern era of drug-eluting stents (DES) are not well understood. Previous studies also …

[PDF][PDF] Ambulatory ECG monitoring in the age of smartphones

D Sanders, L Ungar, MA Eskander, AH Seto - Clevel. Clin. J. Med, 2019 - ccjm.org
Ambulatory electrocardiography (ECG) allows for extended monitoring of arrhythmias in a
real-world setting. This article reviews the currently available ambulatory ECG devices and …

[HTML][HTML] Percutaneous coronary intervention in familial hypercholesterolemia is understudied

L Ungar, D Sanders, B Becerra… - Frontiers in …, 2018 - frontiersin.org
Familial hypercholesterolemia (FH) is a common heritable condition in which mutations of
genes governing cholesterol metabolism result in elevated LDL levels and accelerated …

Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition

L Ungar, F Rodriguez, KW Mahaffey - Coronary Artery Disease, 2016 - journals.lww.com
Despite the use of therapies recommended in practice guidelines for secondary prevention
in patients with atherosclerotic coronary artery disease, the residual risk for cardiovascular …

Stroke outcomes with vorapaxar versus placebo in patients with acute coronary syndromes: insights from the TRACER trial

L Ungar, RM Clare, F Rodriguez, BJ Kolls… - Journal of the …, 2018 - Am Heart Assoc
Background Vorapaxar, a protease‐activated receptor‐1 antagonist, is approved for
secondary prevention of cardiovascular events but is associated with increased intracranial …

[CITATION][C] Appealing Intuition

LDJ Ungar - 2008 - dataspace.princeton.edu
DataSpace: Appealing Intuition Skip navigation DataSpace About Contact Help Search
Explore All Communities & Collections Astrophysical Sciences Chemical and Biological …

Implications of Patient-Reported Treatment Satisfaction for Discontinuation of Rivaroxaban versus Warfarin in ROCKET-AF

F Rodriguez, L Ungar, A Hellkamp… - … Quality and Outcomes, 2017 - Am Heart Assoc
Background: Patient-reported outcomes and satisfaction are important in both trials and clinical
practice and may be associated with treatment adherence. Methods: ROCKET-AF was a …